Tagged with Access

Taiwan Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its strategy for educating key stakeholders, and the importance of talent acquisition and retention.   Taiwan is conducive to attracting R&D…

Sweden Berkeley Vincent, managing director of Janssen in the Nordics and Baltics, discusses the challenges of the digital future for the Swedish affiliate and the whole healthcare industry and highlights Janssen’s strong involvement in the innovative Swedish R&D ecosystem. He also explains why Sweden is in a unique position to lead…

Sweden A relative newcomer to the Nordic countries, Otsuka has successfully built a strong foothold in the region. Pontus Billstam, managing director for the Nordics & Benelux, looks back at the main milestones in the affiliate’s development and explains the importance of the Nordic region for Otsuka as a testbed for…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

Sweden Niels Abel Bonde, general manager of Novo Nordisk Sweden, explains the strategic significance of the Swedish market as an innovation-driven environment ideal to run pilot launches and real-world studies. He also breaks down the performance of the affiliate in its main therapeutic areas, as well as the positives and negatives…

Egypt Amre Mamdouh, vice president & area general manager for Egypt and North Africa at GSK, explains how GSK has been able to hold its leadership position in Egypt despite economic difficulties. He also highlights the government’s prioritization of healthcare and the role of GSK as a partner of national campaigns,…

China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…

Egypt Ashraf Elkhouly, executive director of the Egyptian Society for Pharmaceutical Research, discusses how recent healthcare reforms will help to attract more investment to Egypt and the importance of public-private partnerships for improving the country’s healthcare system.   In collaboration with the government, we started to look into possibilities on how…

Canada Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new national ‘pharmacare’ program being proposed to remedy this situation, Pamela Fralick of Innovative Medicines Canada outlines the strengths and weaknesses of the proposal on the table and…

Egypt Ramez Mohsen, managing director at Janssen for Egypt, Jordan, Libya & Sudan, highlights how the company is driving real access to treatments in Egypt through collaboration with various stakeholders. He also assesses Egypt’s attractiveness for clinical trials and the initial results of the government’s prioritization of healthcare.   As the…

Egypt Christelle Saghbini, the newly appointed chairman & managing director of Sanofi for Egypt & Sudan, highlights her strategic roadmap for bringing access to innovative medicines to Egypt. She also explains how Sanofi is a strong partner in the government’s efforts to improve the level of healthcare in the country.  …

Korea Nic Horridge was recently appointed president of Roche Korea, having spent an extended period in emerging Asian markets. He shares his vision for the Korean affiliate, focused on bringing Roche’s extensive global pipeline of innovative medicines to Korean patients, making personalized healthcare a reality in clinics and championing Korea as…